BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24323312)

  • 1. Detection of residual tumor following radiofrequency ablation of liver metastases using 18F-FDG PET/PET-CT: a systematic review and meta-analysis.
    Zheng JH; Chang ZH; Han CB; Ma JT; Liu ZY; Lu ZM; Guo QY
    Nucl Med Commun; 2014 Apr; 35(4):339-46. PubMed ID: 24323312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic performance of
    Samim M; Molenaar IQ; Seesing MFJ; van Rossum PSN; van den Bosch MAAJ; Ruers TJM; Borel Rinkes IHM; van Hillegersberg R; Lam MGEH; Verkooijen HM
    Surg Oncol; 2017 Mar; 26(1):37-45. PubMed ID: 28317583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results.
    Travaini LL; Trifirò G; Ravasi L; Monfardini L; Della Vigna P; Bonomo G; Chiappa A; Mallia A; Ferrari M; Orsi F; Paganelli G
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1316-22. PubMed ID: 18338164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors.
    Chen W; Zhuang H; Cheng G; Torigian DA; Alavi A
    Ann Nucl Med; 2013 Jan; 27(1):58-64. PubMed ID: 23054830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful?
    Liu ZY; Chang ZH; Lu ZM; Guo QY
    Chin Med J (Engl); 2010 Jul; 123(13):1690-4. PubMed ID: 20819630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study.
    Bonichon F; Palussière J; Godbert Y; Pulido M; Descat E; Devillers A; Meunier C; Leboulleux S; de Baère T; Galy-Lacour C; Lagoarde-Segot L; Cazeau AL
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1817-27. PubMed ID: 24042540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
    Donckier V; Van Laethem JL; Goldman S; Van Gansbeke D; Feron P; Ickx B; Wikler D; Gelin M
    J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning.
    Blokhuis TJ; van der Schaaf MC; van den Tol MP; Comans EF; Manoliu RA; van der Sijp JR
    Scand J Gastroenterol Suppl; 2004; (241):93-7. PubMed ID: 15696856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.
    Veit P; Antoch G; Stergar H; Bockisch A; Forsting M; Kuehl H
    Eur Radiol; 2006 Jan; 16(1):80-7. PubMed ID: 15868122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
    Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H
    J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
    Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
    Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT Findings in Portal Vein Thrombosis and Liver Metastases.
    Surasi DS; O'Malley JP; Bhambhvani P
    J Nucl Med Technol; 2015 Sep; 43(3):229-30. PubMed ID: 25655342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of 18F-FDG PET/CT in patients with liver metastases.
    Chua SC; Groves AM; Kayani I; Menezes L; Gacinovic S; Du Y; Bomanji JB; Ell PJ
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis.
    Lin CY; Chen JH; Liang JA; Lin CC; Jeng LB; Kao CH
    Eur J Radiol; 2012 Sep; 81(9):2417-22. PubMed ID: 21899970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.